Sells it“Rinvoq (upadacitinib) is an oral, once-daily selective and reversible JAK inhibitor that is approved to treat the following inflammatory diseases in North America, the European Union and Japan:”
Latest 10-KFY2025PositiveImpairment / charge ·
Skyrizi and Rinvoq more than offset Humira’s biosimilar losses; acquisition-related charges and a tax-rate reversal kept net earnings flat.
Revenue$61.2BYoY +8.6%
Net income$4.2BYoY −1.2%
Latest 10-QQ3 FY2026Positive ·
Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.
Revenue$17.4BYoY +10.3%
Net income$4.2Bvs $186.0M year ago
Latest 8-KLeadership change ·
Jennifer L. Davis resigned from AbbVie’s board following her appointment as Align Technology CEO.
Sells it 12%, $4.5B a year“Otezla is an oral therapy approved for the treatment of adults with plaque psoriasis across all severities (in the United States, Japan and Australia) and moderate-to-severe plaque psoriasis (in other global markets, including Europe); for adults with active psoriatic arthritis; for adults with oral ulcers associated with Behçet’s disease; and for pediatric patients six years of age and older and weighing at least 20 kilograms with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy.”
Latest 10-KFY2025Impairment / charge ·
Repatha and TEZSPIRE growth outweighed ENBREL’s price-led decline; Prolia and XGEVA biosimilars threaten faster erosion.
Revenue$36.8BYoY +10.0%
Net income$7.7BYoY +88.5%
Latest 10-QQ3 FY2026 ·
Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.
Revenue$10.4BYoY +8.5%
Net income$3.9BYoY +20.1%
Latest 8-KPositiveEarningsGuidance raised ·
Repatha and IMDELLTRA sales surge as biosimilars hit Prolia and XGEVA; FY2026 revenue outlook rises to $38.9B–$39.7B.
Latest 8-KLeadership change ·
Former Yum! Brands CEO David Gibbs joins the board, bringing direct customer relationship experience to inform future product launches
Latest 8-KCybersecurity incident ·
Third-party cloud data theft deemed material due to file volume and potential sensitivity, including proprietary and patient health information
Latest 8-KShareholder vote ·
Shareholders rejected a requirement for an independent board chairman and elected all director nominees.
Latest 8-KCEO/CFO change ·
Thomas Dittrich returns from Galderma to succeed retiring CFO Peter Griffith, who stays through January 2027 to support the transition.
Latest 8-KDebt financing ·
Issues senior unsecured notes across four tranches, with maturities extending to 2056.
In development“Our pipeline is focused on four bispecific antibody programs for the treatment of a broad range of I&I indications, as shown in Figure 5 below.”
Sells it 8%, $4.0B a year“Orencia (abatacept) is a biologic and a fusion protein indicated for (i) the treatment of adult patients with moderately to severely active RA, (ii) the treatment of patients 2 years of age and older with moderately to severely active polyarticular JIA, (iii) the treatment of patients 2 years of age and older with active PsA and (iv) the prophylaxis of aGVHD, in combination with a calcineurin inhibitor and methotrexate in certain adult and pediatric patients.”
Latest 10-KFY2025MixedImpairment / charge ·
Reblozyl, Breyanzi and Camzyos gains offset Revlimid erosion; lower acquisition charges drove the GAAP earnings rebound.
Revenue$48.2BYoY −0.2%
Net income$7.1Bvs −$8.9B year ago
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.
In development“We are also advancing ELA822, a novel SIRPg-specific monoclonal antibody designed to selectively deplete activated T cells, with potential applications across chronic T cell-mediated immune and inflammatory diseases.”
Supplies it“Our relationships with leading partners like AbbVie, Takeda, Lundbeck, NVIDIA, Lambda, Revolution Medicines, Jazz Pharmaceuticals, and Bayer demonstrate meaningful external interest in our platform, and are expanding the impact of our platform to additional target classes (for example, G protein-coupled receptors), additional therapeutic indications (for example, neurology, gastrointestinal, inflammation and immunology), and additional small-molecule mechanisms of action (for example, molecular glues, and glue degraders).”
Sells it 8%, $5.2B a year“For the treatment of adults and pediatric patients aged 6 years or older with moderate to severe plaque psoriasis; adults with active psoriatic arthritis; adults with ankylosing spondylitis; and adults with active non-radiographic axial spondyloarthritis.”
Latest 10-KFY2025PositiveImpairment / charge ·
Mounjaro and Zepbound volume drove growth despite lower realized U.S. prices; Lilly is expanding manufacturing capacity.
Revenue$65.2BYoY +44.7%
Net income$20.6BYoY +94.9%
Latest 10-QQ3 FY2026PositiveImpairment / charge ·
Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.
In development“Our initial focus is on autoimmune, inflammatory and allergic diseases that are characterized by large patient populations, significant unmet need and well-validated disease biology that support clear applications for our LYTAC technology.”
In development“By directly inhibiting NLRP3 upstream, we aim to broadly reduce the activity of the entire sterile inflammation pathway, thereby reducing RIR and modifying the course of cardiovascular and neurologic diseases.”
Supplies it“We have entered into drug discovery collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutic areas, including programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis.”
Latest 10-KFY2025MixedRestructuring ·
Novartis collaboration work and hosted-software sales drove growth, but higher delivery costs squeezed gross margin.
In development“Our mission is to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting validated disease pathways.”